Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Res. 2007 Jan 15;67(2):573-9.

An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth.

Author information

  • 1Department of Pharmaceutical Chemistry, Thoracic Oncology Labratory, University of California San Francisco, and Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Naoaki.Fujii@stjude.org

Erratum in

  • Cancer Res. 2007 Mar 1;67(5):2389.

Abstract

Recent progress in the development of inhibitors of protein-protein interactions has opened the door for developing drugs that act by novel and selective mechanisms. Building on that work, we designed a small-molecule inhibitor of the Wnt signaling pathway, which is aberrantly activated across a wide range of human tumors. The compound, named FJ9, disrupts the interaction between the Frizzed-7 Wnt receptor and the PDZ domain of Dishevelled, down-regulating canonical Wnt signaling and suppressing tumor cell growth. The antitumorigenic effects of FJ9 were pronounced, including induction of apoptosis in human cancer cell lines and tumor growth inhibition in a mouse xenograft model. FJ9 is thus among the first non-peptide inhibitors to show therapeutic efficacy through disruption of PDZ protein-protein interactions.

PMID:
17234765
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk